Acteris Inc., (Acteris), a biotechnology company focused on developing innovative immunotherapies and immunodiagnostics to treat cancer, today announced the publication of research findings in Nature elucidating cancer mechanisms of action that correlate with patient responses to a new class of PD1/PDL1 blocking therapies for melanoma. Specifically, the team validated a signature that predicted response to anti-PD1 therapy. The article, titled “PD-1 Blockade Induces Responses by Inhibiting Adaptive Immune Resistance,” is appearing in the November 27 issue of Nature, 516.
Acteris plans to apply these new discoveries to develop novel cancer immunotherapies and, through partnerships with pharmaceutical and biotechnology companies, improve the development of early-stage therapies to select optimal indications and optimize patient responses.
By monitoring immune activity in cancer patients, the researchers were able to detect cellular signatures indicative of treatment success with anti-PD1 therapies. Paul C. Tumeh, MD, lead author on the Nature article and Assistant Professor of Dermatology described these findings, and in particular the interactions between specific types of immune cells with specific types of tumor cells, as extending the current understanding of this new class of agents and providing direction to develop new generations of compounds.
Antoni Ribas, MD, PhD, senior physician scientist on the article, Professor of Hematology and Oncology and Director of the Johnson Comprehensive Cancer center Tumor Immunology Program Area noted that approximately one-third of patients with advanced melanoma respond to anti-PD1 therapy. A key challenge has been to predict which patients are not likely to respond. By applying these findings to the emerging clinical paradigms, Dr. Ribas believes that the discoveries can provide significant contributions to melanoma, as well as other solid tumors, for physicians, patients, and their families.
According to the study protocols, the researchers monitored melanoma patients receiving anti-PD-1 therapy using a combination of quantitative proteomics and pathologic screening. Patients were evaluated in terms of response to therapy and tumor regression. Combining clinical informatics with quantitative proteomics, the investigators prospectively predicted responses. The publication’s authors include co-founders of Acteris, including Drs. Tumeh and Ribas, as well as David Elashoff, PhD, Professor of Medicine and Biostatistics at UCLA and Director of the Department of Medicine Statistics Core.
“We are extremely pleased with the scientific team’s vision, innovation, and groundbreaking discoveries in cancer immunotherapy,” said Daniel Dornbusch, CEO of Acteris. “The Acteris team’s results highlight the potential to apply the use of personalized medicine to the revolutionary field of cancer immunotherapy. We believe that applying this platform to selection, development, and use of cancer immunotherapies may substantially improve patient outcomes and further transform drug R&D this space.”
Acteris, Inc. is a privately held development stage biotechnology company engaged in improving development and use of novel cancer immunotherapeutic products. It focuses on targeting cancer immunotherapeutic products to specific tumors, patients, and therapeutic combinations to maximize patient outcomes. Acteris is based in San Francisco, CA. For more information, visit the company’s website at www.acterisinc.com.
Daniel Dornbusch, (888) 774-7472